IL23A and psoriasis: Psoriasis persists as a lifelong disease that rarely improves without treatment, but systemic administration of recent monoclonal antibodies targeting the IL-23/Type 17 T-cell (T17) autoimmune axis is highly effective for psoriasis treatment (3).